486 | La Lettre du Cancérologue • Vol. XVII - n° 10 - décembre 2008
Place de la chimiothérapie orale
DOSSIER THÉMATIQUE
Quelles chimiothérapies
pour quels patients âgés ?
Conclusion
Comme on peut le voir, la chimiothérapie orale chez
le sujet âgé reste encore un domaine imparfaite-
ment exploré. Les données prospectives concernant
les patients âgés de plus de 70 ans sont encore peu
nombreuses, ainsi que celles qui concernent le
quatrième âge : la plus grande prudence reste donc de
mise lors de la prescription de chimiothérapie orale.
Malgré certains inconvénients, la chimiothérapie orale
se prête cependant tout à fait à la population des
patients âgés, puisqu’elle peut diminuer les temps de
passage à l’hôpital et les agressions liées à la mise en
place des dispositifs d’accès veineux direct. Cepen-
dant, pour ces patients potentiellement fragiles et
isolés, une présence moindre à l’hôpital ne signifie
pas moins de soins, et il nous appartient de repenser
la prise en charge des sujets âgés en chimiothérapie
orale avec un encadrement infirmier, une coordination
ville, hôpital et pharmacien – hôpital de qualité – qui
sont le garant d’une meilleure qualité des soins sans
augmentation de leur coût si l’on prend en compte
l’ensemble de ceux qu’induisent les transports, les
hospitalisations et leurs complications. ■
1. Murray CJ, Lopez AD. Alternative projections of mortality
and disability by cause 1990-2020: Global Burden of Disease
Study. Lancet 1997;349:1498-504.
2. Lebovits AH, Strain JJ, Schleifer SJ et al. Patient noncom-
pliance with self-administered chemotherapy. Cancer
1990;65:17-22.
3. Cramer JA. Enhancing patient compliance in the elderly.
Role of packaging aids and monitoring. Drugs Aging
1998;12:7-15.
4. Kastrissios H, Blaschke TF. Medication compliance as a
featurein drug development. Annu Rev Pharmacol Toxicol
1997;37:451-75.
5. Vestal RE. Aging and pharmacology. Cancer
1997;80:1302-10.
6. Corcoran ME. Polypharmacy in the older patient with
cancer. Cancer Control 1997;4:419-28.
7. King RS. Drug interactions with cancer chemotherapy.
Cancer Pract 1995;3:57-9.
8. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human
cytochrome P450 enzymes in the metabolism of anticancer
agents: implications for drug interactions. Br J Clin Phar-
macol 1995;40:523-30.
9. Le Chevalier T, Brisgand D, Douilland JY et al. Rando-
mized study of vinorelbine and cisplatin versus vindesine and
cisplatin versus vinorelbine alone in advanced non-small-cell
lung cancer: results of a european multicenter trial including
612 patients. J Clin Oncol 1994;12:360-7.
10. Frasci G, Lorusso V, Panza N et al. Gemcitabine plus vinorel-
bine versus vinorelbine alone in elderly patients with advanced
non-small-cell lung cancer. J Clin Oncol 2000;18:2529-36.
11. Bourgeois H, Vermorken J, Dark G et al. Evaluation of oral
versus intravenous dose of vinorelbine to achieve equiva-
lent blood exposures in patients with solid tumours. Cancer
Chemother Pharmacol 2007;60(3):407-13.
12. Sorio R, Robieux I, Galligioni E, et al. Pharmacokinetics
and tolerance of vinorelbine in elderly patients with metas-
tatic breast cancer. Eur J Cancer 1997;33:301-3.
13. Gauvin A, Pinguet F, Culine S et al. Bayesian estimate
of vinorelbine pharmacokinetic parameters in elderly
patients with advanced metastatic cancer. Clin Cancer
Res 2000;6:2690-5.
14. Miller AA, Rosner GL, Ratain MJ et al. Pharmacology of
21-day oral etoposide given in combination with i.v. cisplatin
in patients with extensive-stage small-cell lung cancer: a
cancer and leukemia group B study (CALGB 9062). Clin
Cancer Res 1997;3:719-25.
15. De Jong RS, Hofstra LS, Willemse PH et al. Effect of
low-dose oral etoposide on serum CA-125 in patients
with advanced epithelial ovarian cancer. Gynecol Oncol
1997;66:197-201.
16. Fleming GF, Waggoner SE, Rotmensch J et al. Phase II
study of 96-h continuous-infusion etoposide and doxoru-
bicin with bolus cyclophosphamide in refractory epithelial
ovarian cancer. Gynecol Oncol 1997;65:42-5.
17. Niitsu N, Umeda M. Evaluation of long-term daily admi-
nistration of oral low-dose etoposide in elderly patients with
relapsing or refractory non-Hodgkin’s lymphoma. Am J Clin
Oncol 1997;20:311-4.
18. Gridelli C, Rossi A, Scognamiglio F et al. Carboplatin
plus oral etoposide in elderly patients with advanced non-
small-cell lung cancer. A phase II study. Anticancer Res
1997;17:4755-8.
19. Dorr RT, von Hoff DD. Cancer chemotherapy handbook,
2nd ed. Norwalk, CT: Appleton & Lange, 1994.
20. McEvoy G. AHFS 2000. Drug information. Bethesda, MD:
American Society of Health System Pharmacists, 2000.
21. Miller AA, Rosner GL, Ratain MJ et al. Pharmacology of
21-day oral etoposide given in combination with i.v. cisplatin
in patients with extensive-stage small-cell lung cancer: a
cancer and leukemia group B study (CALGB 9062). Clin
Cancer Res 1997;3:719-25.
22. Aita P, Robieux I, Sorio R et al. Pharmacokinetics of oral
etoposide in patients with hepatocellular carcinoma. Cancer
Chemother Pharmacol 1999;43:287-94.
23. Tew KD, Colvin M, Chabner BA. Alkylating agents. In:
Chabner BA, Longo DL (eds). Cancer chemotherapy and
biotherapy: principles and practice, 2nd ed. Philadelphia:
Lippincott-Raven, 1996:297-332.
24. Chabner BA, Longo DL. Cancer chemotherapy and
biotherapy. Principles and Practice. Philadelphia, PA:
Lippincott-Raven, 1996.
25. Yung WK, Prados MD, Yaya-Tur R et al. Multicenter phase
II trial of temozolomide in patients with anaplastic astrocy-
toma or anaplastic oligoastrocytoma at first relapse. Temodal
Brain Tumor Group. J Clin Oncol 1999;17:2762-71.
26. Jen JF, Cutler DL, Pai SM et al. Population pharmaco-
kinetics of temozolomide in cancer patients. Pharm Res
2000;17:1284-9.
27. Brada M, Judson I, Beale P et al. Phase I dose-escala-
tion and pharmacokinetic study of temozolomide (SCH
52365) for refractory or relapsing malignancies. Br J Cancer
1999;81:1022-30.
28. Van Cutsem E, Findlay M, Osterwalder B et al. Capeci-
tabine, an oral fluoropyrimidine carbamate with substantial
activity in advanced colorectal cancer: results of a rando-
mized phase II study. J Clin Oncol 2000;18:1337-45.
29. Feliu J, Escudero P, Llosa F et al. Capecitabine as first-
line treatment for patients older than 70 with metastatic
colorectal cancer. An oncopaz cooperative group study.
J Clin Oncol 2005;23:3104-11.
30. Cassidy J, Twelves C, Cameron D et al. Bioequivalence
of two tablet formulations of capecitabine and exploration
of age, gender, body surface area, and creatinine clearance
as factors influencing systemic exposure in cancer patients.
Cancer Chemother Pharmacol 1999;44:453-60.
31. Twelves C, Glynne-Jones R, Cassidy J et al. Effect of
hepatic dysfunction due to liver metastases on the pharma-
cokinetics of capecitabine and its metabolites. Clin Cancer
Res 1999;5:1696-702.
32. Szatrowski TP. Correspondence from Roche Laboratories
Inc., 2000.
Références bibliographiques